Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint

PURPOSE: CEP-701 is a potent inhibitor of trk receptors that causes cell death in prostate cancer (PC) models. CEP-701 binds to serum proteins and a preprostatectomy study was performed to assess prostate tissue penetration and clinical response to CEP-701. METHODS: Growth assays and Western blot an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Collins, Connie, Carducci, Michael A., Eisenberger, Mario A., Isaacs, John T., Partin, Alan W., Pili, Roberto, Sinibaldi, Victoria J., Walczak, Janet S., Denmeade, Samuel R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4124640/
https://ncbi.nlm.nih.gov/pubmed/17786033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados